Medicare and Medicaid may soon cover the cost of weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound under a new experimental program. These GLP-1 drugs, known for their high price tags, have gained popularity for their effectiveness in treating obesity and diabetes. The program aims to assess the potential health and economic benefits of providing access to these medications for eligible beneficiaries. The decision could significantly impact access to treatment for millions and influence healthcare spending on obesity-related conditions.